AI CuratorAI-generated

Research summary · 14 d ago

AI summary · not yet reviewedHuman studyPhase 3Published in a peer-reviewed journal

Human Subjects in Phase 3 Programs Evaluating MS Treatments

In a study involving 15 treated-reference arms from nine Phase 3 programs, the annualized relapse rate (ARR) significantly declined in the BTK inhibitor-era programs (0.109-0.140) compared to earlier periods (0.370 in TEMSO, 0.320 in TOWER). Prior-year relapse activity was positively correlated with ARR, and disability outcomes varied by reporting methods.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42858119)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not yet assessed
Mechanism: Not yet assessed
Evidence strength: Not yet assessed
Outcome: Not yet assessed

Why it matters

These findings suggest that treatments in the BTK inhibitor era may be more effective at reducing relapse rates in MS. However, the data reflects associations and does not imply causation or effectiveness for individual treatments.

What this does not prove

The study's descriptive nature does not confirm causative mechanisms, and the disability trends were dependent on specific reporting metrics.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 15 · treated-reference arms from nine Phase 3 programs
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: Not reported
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceComparator Event Rates, Baseline Activity, and Operational Selection Pressure in Relapsing Multiple Sclerosis Trials: A Meta-Epidemiological Analysis. ↗DOI: 10.1111/ene.70781

Supporting passages (7)

study phaseWe analyzed 15 treated-reference arms from nine Phase 3 programs.

subjectsWe analyzed 15 treated-reference arms from nine Phase 3 programs.

sample sizeWe analyzed 15 treated-reference arms from nine Phase 3 programs.

sample size basisWe analyzed 15 treated-reference arms from nine Phase 3 programs.

peer reviewedJournal: European journal of neurology

findingsRESULTS: Reference-arm ARR declined from 0.370 in TEMSO and 0.320 in TOWER to 0.109-0.140 in BTK inhibitor-era programs (ρ = -0.906; 95% CI, -0.985 to -0.279; n = 15).

limitationsAssociations were descriptive; disability outcomes were audited separately.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.